Skip to Content

FDA Review Finds Pfizer COVID-19 Vaccine Effective After First Dose

TUESDAY, Dec. 8, 2020 -- New data released Tuesday by the U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee suggest that Pfizer's two-dose COVID-19 vaccine works well protecting recipients against COVID-19.

The committee is scheduled to meet on Thursday to consider the Pfizer/BioNTech COVID-19 vaccine for emergency use authorization, CNBC reported.

According to the FDA, the data from Pfizer's COVID-19 vaccine trials were "consistent" with the agency's recommendations for an emergency use authorization. The data show that the vaccine provides protection after the first dose and that two doses are "highly effective" in preventing COVID-19.

"As such, FDA has determined that the Sponsor has provided adequate information to ensure the vaccine's quality and consistency for authorization of the product under an EUA," the agency said.

Today, the United Kingdom began inoculating its citizens with the Pfizer/BioNTech vaccine. The United States is expected to decide on the emergency approval of the vaccine before the end of the week, CNBC reported.

CNBC Article

FDA Briefing Document

© 2021 HealthDay. All rights reserved.

Posted: December 2020

Read this next

Tocilizumab Does Not Improve Outcomes in Severe COVID-19

THURSDAY, Jan. 21, 2021 -- Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19...

Mortality Decreased for COVID-19 ICU Patients Over Time

THURSDAY, Jan. 21, 2021 -- For adults with COVID-19-related critical illness admitted to the intensive care unit (ICU), mortality has decreased over time, according to a study...

President Biden Unveils Details of National Pandemic Response Plan

THURSDAY, Jan. 21, 2021 -- A day after his inauguration, President Joe Biden plans to unveil a new, far-reaching pandemic response plan. He will also issue executive orders that...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.